raloxifene hydrochloride has been researched along with Thromboembolism in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 18 (78.26) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, R; Griffin, JC; Nelson, HD; Smith, ME | 1 |
| Ancona, E; Berretta, R; Bertocco, A; Capobianco, G; D'Antona, D; Di Gangi, S; Gizzo, S; Nardelli, GB; Noventa, M; Patrelli, TS; Saccardi, C; Vacilotto, A | 1 |
| Fu, R; Griffin, JC; Humphrey, L; Nelson, HD; Nygren, P; Smith, ME | 1 |
| Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
| Berg, AO | 1 |
| Baranowski, B; Blumenthal, RS; Dowsett, SA | 1 |
| Kurebayashi, J | 1 |
| Altan, M; Buyukcelik, A; Dogan, M; Doruk, H; Utkan, G; Yalcin, B; Yalcin, S | 1 |
| Baytan, S; Bozkaya, H; Eminagaoglu, S; Karahan, SC; Ozeren, M; Ozgur, M; Unsal, M | 1 |
| Andersen, TO; Eilertsen, AL; Qvigstad, E; Sandset, PM; Sandvik, L | 1 |
| Vastag, B | 1 |
| Barrett-Connor, E; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; McNabb, MA; Mosca, L; Wenger, NK | 1 |
| Pines, A | 1 |
| Johnston, JA; Klein, R; Meadows, ES; Ohsfeldt, RL; Rousculp, MD; Smolen, L | 1 |
| Eilertsen, AL; Hemker, HC; Liestøl, S; Mowinckel, MC; Sandset, PM | 1 |
| Reeder, JG; Vogel, VG | 1 |
| Bjarnason, NH; Black, D; Cauley, JA; Costa, A; Cummings, SR; Eckert, S; Glusman, JE; Grady, D; Jordan, VC; Krueger, KA; Lippman, ME; Morrow, M; Nickelsen, T; Norton, L; Powles, TJ | 1 |
| Body, JJ; Sternon, J | 1 |
| Cuzick, J | 1 |
| Barrett-Connor, E | 1 |
7 review(s) available for raloxifene hydrochloride and Thromboembolism
| Article | Year |
|---|---|
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Fractures, Bone; Humans; Medication Adherence; Patient Participation; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; Thromboembolism; Treatment Outcome | 2013 |
Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications.
Topics: Blood Coagulation; Bone and Bones; Breast; Breast Neoplasms; Contraindications; Endometrium; Female; Humans; Hypercholesterolemia; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Thromboembolism | 2013 |
Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
Topics: Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Norpregnenes; Raloxifene Hydrochloride; Stroke; Tamoxifen; Thromboembolism | 2009 |
[Additional effect of SERM: mammary gland].
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, LDL; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism | 2004 |
Breast cancer risk management.
Topics: Antineoplastic Agents; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Humans; Primary Health Care; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; United States; Women's Health | 2007 |
Future possibilities in the prevention of breast cancer: breast cancer prevention trials.
Topics: Adult; Aged; Anticarcinogenic Agents; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Forecasting; Hormone Replacement Therapy; Humans; Incidence; Menopause; Meta-Analysis as Topic; Middle Aged; Neoplasm Proteins; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome | 2000 |
Raloxifene: risks and benefits.
Topics: Breast Neoplasms; Endometrial Neoplasms; Endometrium; Female; Hot Flashes; Humans; Morbidity; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Thromboembolism | 2001 |
6 trial(s) available for raloxifene hydrochloride and Thromboembolism
| Article | Year |
|---|---|
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cataract; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Uterus | 2010 |
The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
Topics: Administration, Oral; Antigens; Calcium, Dietary; Carboxypeptidase B2; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Plasminogen Activator Inhibitor 1; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thromboembolism; Tissue Plasminogen Activator | 2005 |
Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.
Topics: Antineoplastic Agents, Hormonal; Blood Coagulation; Blood Coagulation Tests; Bone Density Conservation Agents; Drug Therapy, Combination; Estradiol; Female; Hormone Replacement Therapy; Humans; Middle Aged; Norethindrone; Norethindrone Acetate; Norpregnenes; Raloxifene Hydrochloride; Thromboembolism | 2006 |
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Thromboembolism | 2006 |
Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Topics: Activated Protein C Resistance; Administration, Oral; Blood Coagulation; Dose-Response Relationship, Drug; Drug Combinations; Estradiol; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Norethindrone; Norethindrone Acetate; Norpregnenes; Postmenopause; Protein C; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tablets; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2007 |
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
Topics: Aged; Breast Neoplasms; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Thromboembolism | 1999 |
10 other study(ies) available for raloxifene hydrochloride and Thromboembolism
| Article | Year |
|---|---|
ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Number 39, October 2002. Selective estrogen receptor modulators.
Topics: Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Endometrium; Female; Genitalia, Female; Hot Flashes; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism | 2002 |
Chemoprevention of breast cancer: recommendations and rationale.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism | 2003 |
Cardiovascular effects of raloxifene: the arterial and venous systems.
Topics: Arteries; Arteriosclerosis; Biomarkers; Female; Humans; Inflammation Mediators; Lipids; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thromboembolism; Veins | 2004 |
Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Topics: Breast Neoplasms; Confounding Factors, Epidemiologic; Cyclooxygenase 2; Double-Blind Method; Drug Synergism; Enzyme Inhibitors; Female; Humans; Incidence; Membrane Proteins; Osteoporosis, Postmenopausal; Prostaglandin-Endoperoxide Synthases; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Thromboembolism; Treatment Outcome; United States | 2005 |
Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Contraindications; Controlled Clinical Trials as Topic; Drug Approval; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome; United States; United States Food and Drug Administration; Uterine Neoplasms | 2006 |
Lessons from RUTH.
Topics: Breast Neoplasms; Coronary Artery Disease; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism | 2006 |
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Risk; Thromboembolism | 2007 |
Raloxifene for postmenopausal osteoporosis.
Topics: Bone Density; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Half-Life; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Thromboembolism | 1998 |
[Raloxifene (Celvista, Evista)].
Topics: Arteriosclerosis; Bone and Bones; Breast Neoplasms; Controlled Clinical Trials as Topic; Endometrium; Female; Fractures, Bone; Heart Diseases; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism; Uterine Hemorrhage | 2000 |
Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
Topics: Breast Neoplasms; Clinical Trials as Topic; Contraindications; Diabetes Mellitus; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures; Thromboembolism; Uterine Neoplasms | 2000 |